A new viral infection has emerged in recent years in the Far East. Similar to the polio virus, the virus is transmitted by contact and presents as hand, foot and mouth disease. HFMD is generally a mild disease, however, more recently links have been made between the virus and more serious complications, for example, a patient may also develop "aseptic" or viral meningitis. Dr Joseph Santangelo, Chief Operating Officer, InViragen presented at the World Vaccine Congress 2012 in Washington on the development of the EV71 vaccine, which has now completed a Phase 1 trial and is now progressing into Phase 2. He also discussed the impact of the disease, the countries affected and clearly demonstrated the necessity for the EV71 vaccine project. Tell us your views on the new EV71 vaccine below!
Why not download the full presentation and discover more about the Vaccine development for EV71 – a new emerging viral infection in the Far East
Â· Developing a prophylactic EV71 vaccine to reduce disease transmission
Â· An inactivated whole viral particle based vaccine provides the full repertoire of antigenic structures necessary for a broadly protective vaccine
Â· Phase 3 clinical trial result of EV71